Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells
TO THE EDITOR:
Related Articles
Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have
Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have
Genomic landscape of Down syndrome–associated acute lymphoblastic leukemia
Key Points. Using whole-genome sequencing and RNA-seq, we characterized the genomic landscape of 295 DS-ALL cases and identified 15 distinct subtypes.DS-ALL exh
All about Down syndrome ALL
Children with Down syndrome (DS) have a 20 times higher risk of developing acute lymphoblastic leukemia (DS-ALL). In this issue of Blood, Li et al1 report…
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
Key Points. Non-Restrictive diet is non-inferior to traditional Protective diet during neutropenia after HSCT.In multivariable analysis, multiple myeloma diagno
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
Key Points. Non-Restrictive diet is non-inferior to traditional Protective diet during neutropenia after HSCT.In multivariable analysis, multiple myeloma diagno
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
Key Points. Non-Restrictive diet is non-inferior to traditional Protective diet during neutropenia after HSCT.In multivariable analysis, multiple myeloma diagno
